Filing search / Incannex Healthcare Limited / "Chronic"

8-K

EX-99.1

IXHL Incannex Healthcare Limited

24 Oct 24

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

7:30am

biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced … programs hold great therapeutic potential for chronic conditions with unmet patient needs, including obstructive sleep apnea, generalized anxiety

8-K

EX-99.1

IXHL Incannex Healthcare Limited

30 Sep 24

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

4:01pm

developing innovative medicines for people with serious chronic diseases and significant unmet medical needs, today reported fiscal full year financial … for patients living with serious chronic diseases and significant unmet needs. The company is advancing oral synthetic cannabinoid and psilocybin drug

10-K

2024 FY

IXHL Incannex Healthcare Limited

30 Sep 24

Annual report

7:30am

We are a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for patients living with serious chronic diseases … the lives of people suffering from serious, chronic conditions and unmet medical needs. Our three lead programs were created internally and prioritized

8-K

EX-99.1

IXHL Incannex Healthcare Limited

10 Sep 24

Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors

8:00am

with chronic diseases and significant unmet medical needs, today announced it has entered into an agreement to issue up to $10 million in secured convertible … living with chronic diseases and significant unmet need. With three programs currently in Phase 2/3 and Phase 2 development, Incannex is advancing

S-1/A

IXHL Incannex Healthcare Limited

17 Jul 24

IPO registration (amended)

8:47am

includes snoring and waking up gasping for air. This relatively common and chronic disorder is underdiagnosed and inadequately treated … , following the commencement of patient dosing for the Phase 2/3 clinical trial in May 2024. IHL-216A for Concussion/Traumatic Brain Injury and Chronic

S-1

dh280gc w8

3 Jul 24

IPO registration

6:29am

8-K

EX-99.1

l6dgqhq2

16 Apr 24

Incannex Healthcare Inc. Quarterly Update, Q1 2024

9:30am

8-K

EX-99.1

njcn hc1jzmul

24 Jan 24

Other Events

4:30pm

6-K

EX-99.1

2lfdzr5scxn

1 Sep 23

Report of Foreign Private Issuer

12:00am

20-F

i4kk3qqy cs7m17itqs

28 Oct 22

Annual report (foreign)

6:31am

6-K

EX-99.1

jf7faku5

19 Sep 22

Report of Foreign Private Issuer

9:38pm

6-K

EX-99.1

381qr3x08m1rb wo

28 Jul 22

Incannex Healthcare Quarterly Activities Report and Appendix 4C

2:35pm

6-K

EX-99.3

vcp5rb0

12 May 22

Report of Foreign Private Issuer

9:25am

20FR12B/A

gjawi1

24 Feb 22

Initial registration of securities (foreign private issuers) (amended)

3:42pm

20FR12B/A

cxdxp

22 Feb 22

Initial registration of securities (foreign private issuers) (amended)

6:10am

20FR12B

0o55pzk

24 Jan 22

Initial registration of securities (foreign private issuers)

8:18pm

F-1/A

mlm27uz182asm7kq

7 Dec 21

Registration statement (foreign) (amended)

5:21pm

F-1/A

6i4675s1chtpv

23 Nov 21

Registration statement (foreign) (amended)

3:28pm

F-1/A

bgarf f6d2

3 Nov 21

Registration statement (foreign) (amended)

6:06am